Clinicopathological characteristics and the relationship of PD-L1 status, tumor mutation burden, and microsatellite instability in patients with esophageal carcinoma
Based on our preliminary results, TMB and PD-L1 can serve as potential early screening clinical biomarkers and molecular targets for immune treatment in ESCC. However, there is no apparent statistical association between TMB and PD-L1 expression levels. Furthermore, PD-L1 and TMB may independently influence the efficacy of immunotherapy, highlighting the inadequacy of single-marker detection in effectively predicting treatment outcomes.
Authors
- Suyao Li (ORCID: https://orcid.org/0000-0003-2765-3282)
- Yue Zhou (ORCID: https://orcid.org/0000-0002-1335-5703)
- Junxing Huang (ORCID: https://orcid.org/0009-0000-7728-4126)
- Yongling Yu
- Yirong Xu
- Jinghao Jia
Institutions
- North China University of Science and Technology (CN)
- Nantong University (CN)
- Shanxi Provincial Cancer Hospital (CN)
- The Affiliated Taizhou People's Hospital of Nanjing Medical University (CN)
- Wuxi People's Hospital (CN)
- Nanjing Medical University (CN)
Publication Details
- Journal
- BMC Cancer
- Published
- 2025-03-31
- DOI
- https://doi.org/10.1186/s12885-025-13938-y
- Citations
- 3
- Primary Topic
- Esophageal Cancer Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 6.02